ReviewInternational journal of molecular sciences2015
Plants as Factories for Human Pharmaceuticals: Applications and Challenges.
Review in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it, 250 citations in OpenAlex.
- A Systematic Review of the Protective Actions of Cat's Whiskers (Misai Kucing) on the Central Nervous System.Frontiers in pharmacology · 2020Pooled it
- Purifying recombinant proteins from Nicotiana benthamiana for structural studies.Nature protocols · 2026Review
- Synthetic Biology of Plants and Microbes for Agriculture, Environment, and Future Applications.Chemical reviews · 2026Review
- Production, Delivery, and Regulatory Aspects for Application of Plant-Based Anti-microbial Peptides: a Comprehensive Review.Probiotics and antimicrobial proteins · 2025Review
- Industrial applications of Phanerochaete chrysosporium lignin-degrading enzymes: current status, production challenges, and future directions.World journal of microbiology & biotechnology · 2025Review
- Multiplex CRISPR/Cas9-mediated editing of seven glycosyltransferase homologs inFrontiers in plant science · 2025Article
- Viral vector-based transient expression systems for plant biotechnology research at PUIs.Frontiers in education · 2025Article
- Construction and optimization of a genetic transformation system for efficient expression of human insulin-GFP fusion gene in flax.Bioresources and bioprocessing · 2024Article
- Review
- Study on the change of global ecological distribution ofFrontiers in plant science · 2024Article
- An endogenous promoterFrontiers in plant science · 2024Article
- In vitro and in vivo studies of plant-produced Atezolizumab as a potential immunotherapeutic antibody.Scientific reports · 2023Article
- Review
- Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19.Life (Basel, Switzerland) · 2023Review
- A CRR2-Dependent sRNA Sequence Supports Papillomavirus Vaccine Expression in Tobacco Chloroplasts.Metabolites · 2023Article
- Vasorelaxant Mechanism of Herbal Extracts fromMolecules (Basel, Switzerland) · 2022Article
- Plant-Produced S1 Subunit Protein of SARS-CoV-2 Elicits Immunogenic Responses in Mice.Vaccines · 2022Article
- Ameliorating Fibrosis in Murine and Human Tissues with END55, an Endostatin-Derived Fusion Protein Made in Plants.Biomedicines · 2022Article
- Genetic Containment for Molecular Farming.Plants (Basel, Switzerland) · 2022Review
- Recent Advances in Nattokinase-Enriched Fermented Soybean Foods: A Review.Foods (Basel, Switzerland) · 2022Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Plant molecular farming (PMF), defined as the practice of using plants to produce human therapeutic proteins, has received worldwide interest. PMF has grown and advanced considerably over the past two decades. A number of therapeutic proteins have been produced in plants, some of which have been through pre-clinical or clinical trials and are close to commercialization. Plants have the potential to mass-produce pharmaceutical products with less cost than traditional methods. Tobacco-derived antibodies have been tested and used to combat the Ebola outbreak in Africa. Genetically engineered immunoadhesin (DPP4-Fc) produced in green plants has been shown to be able to bind to MERS-CoV (Middle East Respiratory Syndrome), preventing the virus from infecting lung cells. Biosafety concerns (such as pollen contamination and immunogenicity of plant-specific glycans) and costly downstream extraction and purification requirements, however, have hampered PMF production from moving from the laboratory to industrial application. In this review, the challenges and opportunities of PMF are discussed. Topics addressed include; transformation and expression systems, plant bioreactors, safety concerns, and various opportunities to produce topical applications and health supplements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.